Valuation
- Market cap
- 89,405,000
- Revenue TTM
- $0
- Net income TTM
- $-22,400,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 934,700
- Avg volume
- 571,772
- Day's range
- $1.38 – $1.60
- Shares out
- 63,408,000
- Stochastic %K
- 6%
- Beta
- 1.93
- Analysts
- Strong Sell
- Price target
- $8.60
Company profile
Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR modulator that is in preclinical-stage for the treatment of ulcerative colitis and lung inflammation diseases. It also develops EQ302, a bi-specific inhibitor of IL-15 and IL-21 formulated for oral del...
Show more
Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR modulator that is in preclinical-stage for the treatment of ulcerative colitis and lung inflammation diseases. It also develops EQ302, a bi-specific inhibitor of IL-15 and IL-21 formulated for oral delivery for the treatment of celiac diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 858 240 1200
- Website
- https://www.equilliumbio.com
- Address
- 2223 Avenida De La Playa, Suite 105, La Jolla, United States
Latest news
No headlines yet.
